Project measures / variables set:   Wiltshire4   monocytes_Dox

ID, description, units MPD:52433   monocytes_Dox   monocytes, percent viability   [%]  
doxorubicin study
Measures • dose [µM]:    • control    • 0.046    • 0.137    • 1.235    • 11.1    • 100
Data set, strains Wiltshire4   inbred w/CC7   35 strains     sex: m     age: 10wks
Procedure immune cell quantification
Comparisoncontrol group vs. multiple treatment / dosage groups
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options

Wiltshire4 - monocytes, percent viability





  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary     

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
dose 5 629363.3171 125872.6634 1030.6103 < 0.0001
dose:strain 165 97877.3723 593.1962 4.8569 < 0.0001
Residuals 593 72425.5223 122.1341
strain 33 49265.3346 1492.8889 12.2234 < 0.0001

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDTreatmentMeasure / Variable Description PanelStrains
tested
SexAge
Wiltshire4 52433 immune cell quantification doxorubicin monocytes, percent viability   [%]   control  monocytes_Dox_ctrl inbred w/CC7 35 m 10wks
Wiltshire4 52434 immune cell quantification doxorubicin monocytes, percent viability   [%]   dose: 0.046 µM  monocytes_Dox_A inbred w/CC7 35 m 10wks
Wiltshire4 52435 immune cell quantification doxorubicin monocytes, percent viability   [%]   dose: 0.137 µM  monocytes_Dox_B inbred w/CC7 35 m 10wks
Wiltshire4 52436 immune cell quantification doxorubicin monocytes, percent viability   [%]   dose: 1.235 µM  monocytes_Dox_C inbred w/CC7 35 m 10wks
Wiltshire4 52437 immune cell quantification doxorubicin monocytes, percent viability   [%]   dose: 11.1 µM  monocytes_Dox_D inbred w/CC7 35 m 10wks
Wiltshire4 52438 immune cell quantification doxorubicin monocytes, percent viability   [%]   dose: 100 µM  monocytes_Dox_E inbred w/CC7 35 m 10wks